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ABSTRACT 
RP-HPLC is fast, simple, sensitive, precise, and reproducible (liquid chromatography) method, developed and validated to analyseolmutinib 
bulk dosage form. Using C-18 HPLC column separation was carried out. This was maintained at ambient temperature. During separation mobile 
phase consist of methanol (100 v/v) was delivered at a rate of 1mL/min. Using UV detector analysis was carried out at the wavelength 267.68 
nm. RP-HPLC method was validated by using various parameters like, precision, limit of quantitation (LOQ), linearity and robustness.  The RP-
HPLC method was found to be linear over the concentration ranges from 50-100 μg/mL (r2 =0.999). Retention time for bulk olmutinib was 
found to be 9.349 min. LOQ of method was 5.8540 μg/mL and LOD 3.0536μg/mL. Thus, the developed RP-HPLC method was found to be robust 
and rugged which can be applied for the regular analysis of olmutinib in the bulk as well as pharmaceutical dosage form. 
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INTRODUCTION: 
Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd 
developed an oral third generation epidermal growth factor 
receptor tyrosine kinase inhibitor (EGFR TKI) OlmutinibN-
(3-((2-((4-(4-methylpiperazin-1-
yl)phenyl)aminao)thieno[3,2-d]pyrimidin-4-
yl)oxy)phenyl)acrylamide, for the treatment of non-small 
cell lung cancer(NSCLC). With high affinity epidermal 
growth factor binds to epidermal growth factor receptor 
(EGFR) on cell surface, activating the intrinsic protein-
tyrosine kinase activity of receptor, initiates signal 
transduction cascade which results in various biochemical 
changes in the cell - rises calcium levels, increased protein 
synthesis and increases expression of certain 
genes.Olmutinib was granted breakthrough therapy 
designated in NSCLC by the US FDA on December 2015. 
Olmutinib received its first global approval in South Korea 
for the treatment of patients with locally advanced or 
metastatic EGFR T790M mutation-positive NSCLC on May 
2016. 
Eg. EGFR gene leads to DNA synthesis and cell proliferation. 
The Mutations of EGFR expression or activity results in 
cancer. Olmutinib binds covalently and inhibits activating 
EGFR mutations and overcoming T790M resistance 
mutation (mutation of epidermal growth factor receptor). [1-
4] 
 
Fig 01: Chemical Structure of Olmutinib 
Literature survey reveals that a few spectrophotometric, RP-
HPLC methods are reported for the estimation of Olmutinib 
in combination with other drugs. Main purpose of this work 
is to develop a RP-HPLC method for the determination of 
olmutinib in bulk form to provide more scope in further 
research study on the drug and pharma industry.  
MATERIALS AND METHOD: 
Chemicals: 
Olmutinib was received as a gift sample from Mylan 
Laboratories Limited, Hyderabad, India. HPLC grade 
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methanol and double distilled water as solvent was used for 
the other purpose. 
Instrumentation: 
The chromatographic technique was performed on a 
Shimadzu LC-2010CHT Liquid chromatography with UV-
visible detector and LC-Solution software, reversed phase 
C18 column (Inerstil ODS-3V 5 um 250×4.6 mm), Shimadzu 
analytical balance AY-220, Vacuum micro filtration unit with 
0.45μ membrane filter was used in the study. In Double 
beam UV-visible spectrophotometer (UV-probe 2.32 
software). [5] 
Determination of working wavelength (λmax) 
10 mg of olmutinib was weighed and transferred in to 100 
mL volumetric flask and dissolved in methanol and then 
make a dilution of that stock solution. Prepare 10 µg/mL 
solution by diluting 1 mL to 10 mL with methanol. 
Wavelength of maximum absorption for 10 µg/mL solution 
of the bulk drug in methanol was scanned using UV-Visible 
spectrophotometer within the range of 200-400 nm 
wavelength with methanol as reference. The absorption 
curve shows at 267.68 nm for olmutinib bulk. [6-8] 
Chromatographic condition: 
Mobile phase for this developed method methanol 100% 
and it was filtered through a 0.45μmmembrane filter 
degassed with a helium spurge for 30min and pumped from 
the respective solvent reservoir to the column inerstil C18 
column (250×4.6 mm) at flow rate 1.0 mL/min.This HPLC 
developed method run time was set at 10 min and column 
temperature was maintained at RT. Then prior to inject the 
bulk drug solution in to the column, column was equilibrated 
for at least 30 min with the same mobile phase flowing 
through the system.The eluent was monitored at 267.68 nm. 
Using “LC-Solution” software data was stored and analysed. 
[9-11] 
Selection of mobile phase: 
At the beginning solution of bulk drug olmutinib was 
injected into the HPLC system and run in various solvent 
system. Various mobile phase methanol, water, acetonitrile, 
and phosphate buffer in different ratio were tried and finally 
methanol (100%) was selected as an appropriate mobile 
phase which gave good resolution and acceptable peak 
parameters for bulk olmutinib. [18] 
Evaluation of analytical methods: 
Linearity: 
For the linearity study were prepared suitable dilution 
(ranging from 50-100 μg /mL) of standard stock solution 
using mobile phase. Though linear response was obtained at 
lower concentrations for olmutinib and higher concentration 
range was used to improve signal to noise ratio. Linearity 
was determined by analysing five working standard 
solutions over the concentration range of 50-100 μg /mL for 
olmutinib. [18]  
Limit of detection (LOD): 
The limit of detection (LOD) is the smallest concentration 
that can be detected but not necessarily quantified as an 
exact value. LOD is calculated from the formula, 
LOD = 3.3σ/s 
Where, σ = standard deviation of the response 
S = slope of the calibration curve. 
Limit of Quantification (LOQ): 
The limit quantification (LOQ) is the lowest amount of 
analyte in the sample that can be quantitatively determined 
with precision and accuracy. LOQ is calculated from formula, 
LOQ = 10σ/s 
Where, σ = standard deviation of the response 
S = slope of calibration curve 
Accuracy: 
Accuracy of this method was carried out using one set of 
different standard addition methods at different 
concentration levels80%, 100% and 120%, and then 
comparing the difference between the spiked value 
(theoretical value) and actual found value.[10,11] 
Precision: 
Five sets of aliquots with same concentration (90 μg /mL) 
were prepared and these solutions were analysed to record 
any intra and inter day variations in the results. The results 
obtained for Intra and inter day variations. 
Robustness: 
Robustness of the proposed method for olmutinibwas 
carried out by the slight variation in flow rate, temperature 
and mobile phase ratio. The percentage recovery and RSD 
were noted for olmutinib. 
RESULT AND DISCUSSION: 
Checking resolution of drug and materials: 
The column was saturated with the mobile phase (indicated 
by constant back pressure at desired flow rate). Standard 
solution of olmutinib was injected to get the chromatogram. 
The retention time for olmutinib was found to be 9.349 min. 
It is shown in the Table 1. 
 
Table 1 Resolution of bulk drug 
Drug Ret. Time Area Height Theoretical 
plate 
Tailing factor 
Olmutinib 9.349 32687814 330510 3308.216 0.820 
 
Linearity: 
The data of the peak area vs drug concentration were 
evaluated by linear regression analysis as shown in the 
Table 2 and calibration curve obtained after plotting drug 
concentration vs area shown in the fig. 1. Linear regression 
analysis demonstrated that chromatograph response for the 
drug was highly linear (r2=0.999) in the studied 
concentration range of 50-100 μg/mL. A typical 
chromatogram of olmutinib (50 μg/mL) shown in fig. 1. 
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Fig.1. A typical chromatogram for olmutinib (50μg/mL) 
 
Fig. 2. Calibration curve of Olmutinib 
Table 2. Calibration of Olmutinib 
Sr no. Concentration (μg /mL) Peak area 
1 50 31687814 
2 60 40257278 
3 70 50054020 
4 80 58237139 
5 90 68259861 
6 100 78252828 
Precision: 
The result depicted in the table3a,3b indicated that the given method has sufficient precision as indicated by the corresponding 
values of %RSD ranging 0.15 and 0.18 for intraday as well as  inter day studies respectively. The values of %RSD for both the 
studies are well below 1.0% constructing adequate precision. 
Table. 3a. Intra-day Precision for Olmutinib 
Concentration (μg /mL) Peak area Mean (n=5) S.D. %RSD 
90 78252828    
90 79620844    
90 75528703 76528703 11622.96 0.15 
90 70429855    
90 78069865    
 
Table. 3b. Inter-day Precision for Olmutinib 
Concentration (μg /mL) Peak area Mean (n=5) S.D. %RSD 
90 77252828    
90 78620844    
90 75528703 76145843 40217.53 0.18 
90 74429855    
90 77069865    
 
 
 
 
 
y = 928617x - 2E+07 
R² = 0.9991 
0
20000000
40000000
60000000
80000000
100000000
0 50 100 150
P
e
ak
 A
re
a 
 
Concentration µg/mL 
Olmutinib   
 
Khandare et al                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):608-611  
ISSN: 2250-1177                                                                                  [611]                                                                                 CODEN (USA): JDDTAO 
Limit of detection and quantification: 
Standard error and slope of linear data is used to predict 
LOD and LOQ of olmutinib and precision was established at 
the predict concentration. The result was shown in the 
table.4 
Table 4 Limit of detection and Limit of quantification 
Limit of detection Limit of quantification 
3.0536μg/mL 5.8540μg/mL 
 
CONCLUSION:  
From the results and discussion, RP-HPLC methods were 
developed and validated as per ICH guidelines Q2 (R1). In 
this paper described for the determination of olmutinib in 
bulk is simple, sensitive and reproducible. The proposed 
methods can be successfully applied for olmutinib without 
any interference in quality control. 
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